762272-97-9

Basic information

• Product Name: 1-(3-bromophenyl)-3-[2-(1-hydroxy-1-methylethyl)phenyl]propan-1-one
• Synonyms: 1-(3-bromophenyl)-3-[2-(1-hydroxy-1-methylethyl)phenyl]propan-1-one
• CAS NO: 762272-97-9
• Molecular Weight: 347.252
• Mol File: 762272-97-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-(3-bromophenyl)-3-[2-(1-hydroxy-1-methylethyl)phenyl]propan-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-bromophenyl)-3-[2-(1-hydroxy-1-methylethyl)phenyl]propan-1-one(762272-97-9)
• EPA Substance Registry System: 1-(3-bromophenyl)-3-[2-(1-hydroxy-1-methylethyl)phenyl]propan-1-one(762272-97-9)

Safety Data

• Hazardous Substances Data: 762272-97-9(Hazardous Substances Data)

Upstream product

• 762272-95-7 2-[3-(3-bromophenyl)-3-hydroxypropyl]benzoic acid methyl ester 
• 165896-48-0 2-[3-(3-bromo-phenyl)-3-oxo-propyl]-benzoic acid methyl ester 
• 762272-99-1 (+/-)-1-(3-bromophenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)-1-propanol 

Downstream Products

• 762272-99-1 (+/-)-1-(3-bromophenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)-1-propanol 
• 287930-77-2 (S,E)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propan-1-ol 
• 762273-01-8 (S)-1-(3-bromo-phenyl)-3-[2-(1-hydroxy-1-methyl-ethyl)-phenyl]-propan-1-ol 
• 1258428-71-5 trans-1-{3-[2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(1-hydroxy-1-methylethyl)phenyl]propan-1-one 

Relevant articles and documents

For the synthesis of montelukast intermediate compound and its preparation method

The invention relates to a pharmaceutical intermediate and a preparation method thereof, and especially relates to an intermediate compound represented by the formula (1) for synthesizing montelukast; wherein in the formula the X' represents a halogen ele

The resolution of important pharmaceutical building blocks by palladium-catalyzed aerobic oxidation of secondary alcohols

The palladium-catalyzed aerobic oxidative kinetic resolution of key pharmaceutical building blocks is described. Substrates investigated are relevant to the enantioselective preparation of Prozac, Singulair, and the promising hNK-1 receptor antagonist from Merck. The latter provides the most selective aerobic oxidative kinetic resolution yet described.